27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
By Sunday night, the U.S. Drug Enforcement Administration is expected to reclassify GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)’s Epidiolex to allow medicinal use. This could open the therapy to a new and promising market.
The Analyst
Morgan Stanley analyst David Lebowitz maintained an Overweight rating on GW with a $197 price target.
The Thesis
Morgan Stanley expects the DEA to drop Epidiolex from Schedule I — the same level as cocaine, heroin and other illegal substances — to Schedule IV, where Xanax, Ambien and Tramadol rank. At worst, it would fall to Schedule III alongside moderately to lowly addictive drugs like codeine and anabolic steroids, Lebowitz said. (See his track record here.)
Regardless of the assignment, the drug would mark a milestone on the U.S. pharmaceutical timeline. Epidiolex, already the first cannabinoid-based therapy to gain FDA approval, would become the first such drug to launch domestically.
The treatment would begin addressing Dravet and Lenox-Gastaut syndromes, which together account for 20,000 U.S. patients, but it could eventually see use in other seizure indications.
“We expect the drug will be a blockbuster, with off label usage driving it to $1.3 billion by [the end of 2025],” Lebowitz said.
Epidiolex is under review by the EMA and could launch in Europe in the first quarter.
Price Action
GW was set to open 3.08 percent higher at $153.80 at the time of publication Wednesday.
Related Links:
420 Investor: Cannabis Drug Approval Creates 'Logic Issue' For The US Government
GW Pharma's Epidiolex Becomes First Cannabis-Based FDA-Approved Drug
Photo courtesy of GW Pharma.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!